High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1β in osteoarthritic synoviocytes by García-Arnandis, Isabel et al.
RESEARCH ARTICLE Open Access
High mobility group box 1 potentiates the
pro-inflammatory effects of interleukin-1b in
osteoarthritic synoviocytes
Isabel García-Arnandis
1, Maria Isabel Guillén
1,2, Francisco Gomar
3, Jean-Pierre Pelletier
4, Johanne Martel-Pelletier
4,
Maria José Alcaraz
1*
Abstract
Introduction: High mobility group box 1 (HMGB1) is released by necrotic cells or secreted in response to
inflammatory stimuli. Extracellular HMGB1 may act as a pro-inflammatory cytokine in rheumatoid arthritis. We have
recently reported that HMGB1 is released by osteoarthritic synoviocytes after activation with interleukin-1beta (IL-
1b) The present study investigated the role of HMGB1 in synovial inflammation in osteoarthritis (OA).
Methods: HMGB1 was determined in human synovium using immunohistochemistry, comparing normal to OA.
OA synoviocytes were incubated with HMGB1 at 15 or 25 ng/ml in the absence or presence of IL-1b (10 ng/ml).
Gene expression was analyzed by quantitative PCR and protein expression by Western Blot and ELISA. Matrix
metalloproteinase (MMP) activity was studied by fluorometric procedures and nuclear factor (NF)-B activation by
transient transfection with a NF-B-luciferase plasmid.
Results: In the normal synovium, HMGB1 was found in the synovial lining cells, sublining cells, and in the vascular
wall cells. The distribution of HMGB1 in OA synovium was similar but the number of HMGB1 positive cells was
higher and HMGB1 was also present in infiltrated cells. In normal synovial membrane cells, HMGB1 was found
mostly in the nuclei, whereas in OA, HMGB1 was generally found mostly in the cytoplasm. In OA synoviocytes,
HMGB1 alone at concentrations of 15 or 25 ng/ml did not affect the production of IL-6, IL-8, CCL2, CCL20, MMP-1
or MMP-3, but in the presence of IL-1b, a significant potentiation of protein and mRNA expression, as well as MMP
activity was observed. HMGB1 also enhanced the phosphorylated ERK1/2 and p38 levels, with a lower effect on
phosphorylated Akt. In contrast, JNK1/2 phosphorylation was not affected. In addition, HMGB1 at 25 ng/ml
significantly potentiated NF-B activation in the presence of IL-1b.
Conclusions: Our results indicate that HMGB1 is overexpressed in OA synovium and mostly present in extracellular
form. In OA synoviocytes, HMGB1 cooperates with IL-1b to amplify the inflammatory response leading to the
production of a number of cytokines, chemokines and MMPs. Our data support a pro-inflammatory role for this
protein contributing to synovitis and articular destruction in OA.
Introduction
The nuclear DNA-binding protein high mobility group
box 1 (HMGB1) can be passively released by necrotic
cells or secreted by macrophages and other myeloid
cells in response to inflammatory stimuli as part of the
inflammatory response to infection or injury (reviewed
in [1]). It is known that pro-inflammatory cytokines
such as IL-1b or TNFa stimulate HMGB1 translocation
into the cytoplasm and release in different cell types,
although TNFa is not the main inducer of extracellular
HMGB1 during synovitis in rheumatoid arthritis
patients [2]. Oxidative stress has also been shown to
induce HMGB1 release potentially through a mitogen-
activated protein kinase (MAPK) and chromosome
region maintenance mechanism [3]. * Correspondence: maria.j.alcaraz@uv.es
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proliferation, migration and differentiation [4-6]. Binding
of HMGB1 to bacterial products might create complexes
inducing innate immune responses and production of
inflammatory mediators. Extracellular HMGB1 interacts
with receptor for advanced glycation end products
(RAGE) and the toll-like receptors (TLR) including
TLR-2 and TLR-4 [1] leading to the activation of mono-
cytes, macrophages and dendritic cells. In addition, the
interaction of HMGB1 with phosphatidylserine on the
cell surface inhibits the phagocytosis of apoptotic neu-
trophils by macrophages [7], which may retard the reso-
lution of inflammation. Nevertheless, recent studies
suggest that HMGB1 alone demonstrates minor pro-
inflammatory activity, which is potentiated through
binding to IL-1b and other inflammatory mediators [8].
H M G B 1p l a y sar o l ea sap r o - inflammatory cytokine
in rheumatoid arthritis and animal models of this dis-
ease. Hence, HMGB1 is overexpressed in synovial tissue
of rheumatoid arthritis patients and its extracellular
form has been related to the progression of arthritis in
animal models [9]. Moreover, RAGE activation by
HMGB1 results in increased invasiveness of fibroblast-
like synoviocytes from rheumatoid arthritis patients [10].
In human articular cartilage, HMGB1 may participate
in endochondral ossification during osteogenesis [11]
and recently, the related protein HMGB2 has been
involved in ageing and osteoarthritis (OA) [12]. Studies
show that HMGB1 [13] and its receptor RAGE [14] are
expressed in OA cartilage. It is also known that stimula-
tion of OA chondrocytes with HMGB1 results in phos-
phorylation of extracellular signal-regulated kinase
(ERK) and nuclear factor-B (NF-B), and matrix metal-
loproteinase (MMP) expression [14]. In addition, activa-
tion of RAGE by advanced glycation end products
(AGEs) in OA chondrocytes and synoviocytes leads to
increased catabolic activity and cartilage degeneration
[15]. Nevertheless, the pro-inflammatory activity of
HMGB1 in synoviocytes and its participation in synovi-
tis during OA remain to be determined. We have
recently reported that HMGB1 is released by OA syno-
viocytes after activation with IL-1b [16], suggesting the
participation of HMGB1 in the inflammatory response
induced by this cytokine. In the present study, we
further investigated the role of HMGB1 in OA synovial
inflammation.
Materials and methods
Specimen selection
Human OA knee synovial membranes were obtained
from patients (12 female, 3 male, aged 69 ± 1 years,
mean ± standard error of the mean (SEM)) undergoing
total knee arthroplasty. All patients fulfilled the Ameri-
can College of Rheumatology criteria for OA of the
knee [17]. Normal knees (2 female, 1 male, aged 72 ±
1.5 years) were obtained within 12 hours of death; the
tissues were examined macroscopically and microscopi-
cally to ensure that only normal tissue was used. This
study was approved by the Institutional Ethical Commit-
tee and is in compliance with all ethical standards and
patients’ consent according to the Declaration of
Helsinki.
Immunohistochemistry of HMGB1 in human synovium
HMGB1 was determined in the human synovium using
immunohistochemistry, comparing normal with OA.
Tissues were processed following two methodologies.
Firstly, we used an HMGB1 antibody that was revealed
with 3,3’-diaminobenzidine (DAB) for reading with light
microscope, and secondly a fluorescent HMGB1 anti-
body for fluorescence microscopy analysis. In brief, the
specimens were dissected and fixed in TissuFix #2
(Chaptec, Montreal, QC, Canada) and processed directly
after acquisition from the donor for immunohistochem-
istry (basal synthesis), as previously described [18]. Sec-
tions of 5 μm of paraffin-embedded specimens were
deparaffinized in toluene and rehydrated in a graded
series of ethanol. The synovium was treated with Triton
X-100 (0.3%) for 20 minutes at room temperature.
Slides were washed in PBS followed by 3% hydrogen
peroxide/methanol for 15 minutes. They were further
incubated for 45 minutes with 1.5% normal serum (Vec-
tor Laboratories, Burlingame, CA, USA) and overlaid
with the rabbit anti-human HMGB1 antibody (1:50 dilu-
tion; Abcam, Cambridge, MA, USA) for 18 hours at 4°C
in a humidified chamber. The second antibody was a
goat anti-rabbit immunoglobulin (Vector Laboratories,
Burlingame, CA, USA) in which slides were incubated
for 45 minutes. For reading with a light microscope,
slides were stained using the avidin-biotin complex
method (Vectastain ABC kit, Vector Laboratories, Bur-
lingame, CA, USA). The colour was developed with
DAB (DAKO Diagnostics Canada Inc., Mississauga, ON,
Canada) without nickel chloride. The slides were coun-
ter-stained with Mayer’s hematoxylin. Each section was
examined under a light microscope (Leitz Orthoplan;
Leica Inc., St-Laurent, QC, Canada) and photographed
with a Retega OEM Fast camera (QImaging, Surrey, BC,
Canada). For detection with fluorescence of Alexa 488
fluorochrome, slides were stained with TSA™ #22 (Invi-
trogen, Burlington, ON, Canada) and mounted with
Vectashield (Vector Laboratories, Burlingame, CA, USA)
containing 4’,6-diamidino-2-phenylindole (DAPI) in
order to stain the nucleus. The slides were examined
under a fluorescence microscope and photographed by a
CoolSNAP cf Photometrics camera (Roper Scientific,
Rochester, NY, USA). Controls were performed to deter-
mine the specificity of staining: i) substitution of the
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(used at the same concentration as the primary anti-
body); ii) immunoadsorbed with 20-fold excess of the
peptide HMGB1; and iii) omission of primary antibody.
Controls showed only background staining.
The presence of the antigen in the synovium was
quantified by determining the number of cells that
stained positive with the distinction between nuclear
and extra-nuclear (cytoplasmic and cell vicinity) stain-
ing. Each synovial membrane was divided into three
microscopic fields (40×; Leitz Orthoplan) and the total
number of cells and those staining positive for the speci-
fic antigen were determined in the lining cells for both
normal and OA, and in the infiltrates for OA specimens.
The final results were expressed as the percentage of
cells staining positive for the antigen with the maximum
score being 100%.
Moreover, the synovial lining cell hyperplasia was
graded on a scale of 0 to 2 as previously described [19],
where 0 = 1 to 2 layers of cells, 1 = 3 to 5 layers, and 2
= 6 or more layers. The layers were counted from the
surface of the membrane to the subsynovial tissue. Each
synovium was graded into three microscopic fields (40×;
Leitz Orthoplan) and the score averaged.
Confocal microscopy
Discrimination of the HMGB1 location within the cells
was confirmed using immunofluorescence followed by
confocal microscopy. In brief, sections of 10 μm of par-
affin-embedded specimens were treated as above. Con-
focal acquisitions were carried out with a Leica TCS
SP5 broadband confocal microscope (St-Laurent, QC,
Canada, which uses confocal point-scanning for optical
sectioning. In addition, it has a spectral imaging detector
allowing tunable emission bands and dye separation.
The system is equipped with the AOBS (Acousto-Opti-
cal Beam Splitter) for optical beam splitting. It has three
lasers: Ar 458/488/514, DPSS 561 and HeNe 633, 543,
594.
Cell culture and treatments
Synovial specimens were finely minced and isolated by
enzymatic digestion with collagenase type 1A (Sigma
Aldrich, St Louis, MO, USA) in DMEM/HAM F12
(Sigma-Aldrich, St Louis, MO, USA) containing penicil-
lin (100 U/ml) and streptomycin (100 μg / m l )a t3 7 ° Ci n
5% carbon dioxide atmosphere for 16 hours. The
digested tissue was filtered through a 70 mm nylon
mesh, washed and centrifuged. Cell viability was greater
than 95% according to the Trypan blue exclusion test.
Collected cells were resuspended in DMEM/HAM F12
(Sigma-Aldrich, St Louis, MO, USA) containing penicil-
lin (100 U/ml) and streptomycin (100 μg/ml) supple-
mented with 10% fetal bovine serum (Sigma-Aldrich, St
Louis, MO, USA) and cultured at 37°C in 5% carbon
dioxide atmosphere until third passage (95% fibroblasts,
detected by immunocytochemistry with anti-collagen I
antibody (Chemicon, Millipore Iberica, Madrid, Spain)).
Synoviocytes were allowed to grow to nearly confluence
and incubated with HMGB1 (HMGBiotech, Milano,
Italy) at 15 or 25 ng/ml and IL-1b (10 ng/ml, Peprotech
EC Ltd, London, UK) or culture medium. Viability stu-
dies were performed for all the experimental conditions.
None of the treatments significantly affected cell viabi-
lity which was more than 90% as tested by Trypan blue
exclusion. The possibility of endotoxin contamination of
HMGB1 was excluded after performing the Limulus test
using the commercial kit from Sigma-Aldrich (St Louis,
MO, USA; data not shown).
Western blot analysis
After stimulation for five minutes with IL-1b (10 ng/
ml), HMGB1 at 15 and 25 ng/ml or IL-1b+HMGB1,
synoviocytes were lysed in 100 μl of buffer (1% Triton
X-100, 1% deoxycholic acid, 20 mM NaCl and 25 mM
Tris, pH 7.4) and centrifuged at 4°C for 15 minutes at
10,000g.P r o t e i n s( 2 5μg) in cell lysates were separated
by 12.5% SDS-PAGE and transferred onto polyvinyli-
dene difluoride membranes. Membranes were blocked
with 3% bovine serum albumin and incubated with
specific antibodies against phosphorylated ERK (Cell
Signaling Technology, Inc., Beverly, MA, USA, dilu-
tion 1:800), phosphorylated or total Akt and ERK
(Cell Signaling Technology, Inc., Beverly, MA, USA;
dilution 1:500), and phosphorylated or total c-Jun N-
terminal kinase (JNK; Cell Signaling Technology, Inc.,
Beverly, MA, USA; dilution 1:250) and p38 (Promega
Corporation, Madison, WI, USA; dilution 1:250) over-
night at 4°C. Finally, membranes were incubated with
peroxidase-conjugated goat anti-rabbit IgG (Dako,
Copenhagen, Denmark) and the immunoreactive
bands were visualized by enhanced chemiluminescence
(GE Healthcare, city, Barcelona, Spain) using the
AutoChemi image analyzer (UVP Inc., Upland, CA,
USA).
Determination of MMP activity
Cells were stimulated with IL-1b (10 ng/ml), HMGB1 at
15 and 25 ng/ml or IL-1b+HMGB1 for 24 hours and
supernatants were harvested, centrifuged and incubated
with p-aminophenyl mercuric acetate for six hours at
37°C to activate MMPs. Aliquots of supernatants were
then transferred to a 96-well plate and after addition of
the 5-FAM peptide substrate (AnaSpec Inc., San Jose,
CA, USA), fluorescence was measured for different
times at 490 nm (excitation)/520 nm (emission) in a
Victor3 microplate reader (PerkinElmer España, Madrid,
Spain).
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Synoviocytes were stimulated with IL-1b (10 ng/ml) for
24 hours, in the presence or absence of HMGB1 at 15
and 25 ng/ml. Supernatants were harvested, centrifuged
and frozen at -80°C until analysis. IL-6, IL-8 and chemo-
kine (C-C motif) ligand 2 (CCL2) levels were deter-
mined by specific ELISA from eBioscience (San Diego,
CA, USA) with sensitivity of 2, 4 and 7 pg/ml, respec-
tively. CCL20 was determined with a specific ELISA
from Raybiotech Inc. (Norcross, GA, USA) with sensitiv-
ity of 1.5 pg/ml. MMP-1 and MMP-13 protein was
quantified in supernatants by using specific ELISAs
from AnaSpec (sensitivity of 8 and 6 pg/ml, respec-
tively), and MMP-3 with the ELISA from Raybiotech
Inc. (sensitivity of 0.3 ng/ml).
Real-time PCR
Following incubation for 24 hours, total RNA was
extracted using the TriPure reagent (Roche Applied
Science, Barcelona, Spain) according to the manufac-
turer’s instructions. Reverse transcription was accom-
plished on 1 μg of total RNA using random primers
(TaqMan reverse transcription reagents, Applied Biosys-
tems, Spain, Madrid). PCR assays were performed in
duplicate on an iCycler Real-Time PCR Detection Sys-
tem using SYBR Green PCR Master Mix (Bio-Rad
Laboratories, Richmond, CA, USA) [20]. Sequences of
primers used have been reported previously [21-24]. For
each sample, differences in threshold cycle (DCt) values
were calculated by correcting the Ct of the gene of
interest to the Ct of the reference gene glyceraldehide-
3-phosphate dehydrogenase. Relative gene expression
was expressed as DDCt with respect to nonstimulated
cells.
Activation of NF-B
Cells were seeded into six-well plates and grown to 50
to 60% confluence. Transient transfection was per-
formed for 45 minutes with 2 μgo ft h er e p o r t e rc o n -
struct NF-B - l u c( S t r a t a g e n e ,L aJ o l l a ,C A ,U S A )a n d1
μg of the internal control pRL-TK (Promega Corpora-
tion, Madison, WI, USA) by the Magnetofection™ sys-
tem (OZ Biosciences, Marseille, France) according to
the manufacturer’s recommendations. The medium
was then replaced and cells were treated for 24 hours
with HMGB1 at 25 ng/ml in the absence or presence
of IL-1b (10 ng/ml). After lysis and centrifugation, ali-
quots of supernatants were used to assay firefly and
Renilla luciferase activity using the Dual-Luciferase
Reporter Assay System kit (Promega Corporation,
Madison, WI, USA). Luminescence was measured in a
Microbeta counter (Wallac, Turku, Finland) and firefly
luciferase activity was normalized to Renilla luciferase
activity.
Statistical analysis
Results are presented as mean ± SEM. Statistical ana-
lyses were performed using one-way analysis of variance
followed by Dunnett’s t-test for multiple comparisons
and two-tailed unpaired Student’s t-test for dual
comparisons.
Results
HMGB1 expression in human synovium
In the normal and OA synovium, HMGB1 was found in
the cells of the synovial lining, sublining cells, and in
the cells of the vascular wall (i.e. cells around the blood
vessels) (Figure 1a). We further performed an analysis of
the percentage of positive synoviocytes in the nuclear
and extra-nuclear (cytoplasmic and cell vicinity) com-
partments of the cells comparing normal (n =3 )w i t h
OA (n = 3). As illustrated in Figure 1b, a statistically
significant decrease in HMGB1 was found in OA cell
nuclei when compared with normal (P < 0.03), and,
although there was more positive staining in the extra-
nuclear (cytoplasm and in the cell vicinity) compart-
ment, this did not quite reach statistical significance (P
< 0.07). In OA synovium, the percentage of infiltrate
cells staining positive in the nuclei (23.6 ± 3.9%) was
significantly less than in the extra-nuclear compartment
(52.4 ± 4.1%; P < 0.007). Moreover, comparison of the
synovial lining layers showed, as expected, more cell
layers in the OA (score:1.3 ± 0.2) than in the normal
(0.6 ± 0.2) synovial membrane.
Experiments performed with the fluorescent antibody
(Figure 2) confirmed that in normal synovial membrane
cells, HMGB1 (green) was found mostly in the nuclei
with some cells showing cytoplasm staining (Figures 2a
to 2c). In OA (Figures 2b to 2d), however, HMGB1 was
generally found mostly in the cytoplasm. For cell infil-
trates (Figures 2e to 2f), the pattern was as for the OA
lining cells, in which HMGB1 was found mostly in the
cytoplasm.
Effect of HMGB1 on cytokine and chemokine production
induced by IL-1b in OA synoviocytes
To determine whether extracellular HMGB1 can modu-
late cytokine and chemokine production in human OA
synoviocytes, cells were incubated with HMGB1 in the
presence or absence of IL-1b (10 ng/ml). This pro-
inflammatory cytokine is present in OA synovial fluid
and cartilage and participates in joint degradation
[25,26]. As expected, stimulation with IL-1b resulted in
the enhanced production of pro-inflammatory cytokines
and chemokines. As shown in Figure (3a to 3d),
although HMGB1 alone at concentrations of 15 or 25
ng/ml did not affect the production of IL-6, IL-8, CCL2
or CCL20, a significant potentiation of these pro-inflam-
matory mediators was observed in the presence of IL-
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mRNA level, with an enhancement of IL-6, IL-8, CCL2
and CCL20 mRNA expression in cells stimulated with
IL-1b (Figures 4a and 4b).
Effect of HMGB1 on MMPs induced by IL-1b in OA
synoviocytes
Cell activation by IL-1b (10 ng/ml) potently induced
MMP gene expression as well as MMP protein and
activity. mRNA expression was measured by real-time
PCR. In cell supernatants, protein levels were measured
by ELISA and MMP activity by a fluorometric proce-
dure. As shown in Figure (5a to 5c), HMGB1 alone did
not induce significant changes in MMP-1, MMP-3 or
MMP-13 protein in cell supernatants, but it potentiated
the stimulating effect of IL-1b for MMP-1 and MMP-3.
In addition, HMGB1 significantly increased MMP-1 and
MMP-3 mRNA expression in the presence of IL-1b
(Figure 6a). These effects were reflected in the levels of
MMP activity released into the medium, which were sig-
nificantly increased by HMGB1 after IL-1b stimulation
(Figure 6b).
Effect of HMGB1 on Akt and MAPK phosphorylation
induced by IL-1b in OA synoviocytes
To determine the possible mechanism of action of
HMGB1, we further examined whether this protein
acts on Akt and MAPK activation. The time of stimu-
lation for a high phosphorylation response was chosen
from previous experiments [see Additional file 1]. As
shown in Figure 7, HMGB1 at both concentrations
studied (15 and 25 ng/ml) increased the phosphory-
lated Akt and ERK1/2 levels. In the presence of IL-1b,
HMGB1 enhanced the phosphorylated ERK1/2 and
p38 levels, with a lower effect on phosphorylated Akt.
In contrast, JNK1/2 phosphorylation was not affected
by HMGB1 either in the presence or absence of IL-1b
stimulation.
Figure 1 Expression of HMGB1 protein in human synovium. (a) Representative immunohistochemical sections of normal (n =3 )a n d
osteoarthritic (n = 3) human synovium with high mobility group box 1 (HMGB1) revealed in 3,3’-diaminobenzidine (DAB). Arrows indicate
HMGB1 positive cells. Original magnification × 100. (b) Histograms of normal and osteoarthritic positive cells (%) in the synovial lining cell
nucleus and cytoplasm and vicinity. Data are expressed as mean ± standard error of the mean (n = 3). *P < 0.05 with respect to normal.
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OA synoviocytes
NF-B is a main regulator of pro-inflammatory and
degradative genes in the joint. As IL-1b [27] and
HMGB1 [28] cell stimulation results in the activation of
this pathway in different cell types, we studied the possi-
ble participation of this mechanism in the pro-inflam-
matory effects of HMGB1 in OA synoviocytes. HMGB1
treatment in nonstimulated cells resulted in increased
transcriptional activity, although it did not reach statisti-
cal significance. Of note, HMGB1 at 25 ng/ml signifi-
cantly potentiated NF-B activation in the presence of
IL-1b (Figure 8).
Discussion
Synovial inflammation has been demonstrated in tissue
samples of OA patients and may be related to disease
progression [17,29,30]. Several lines of evidence support
the involvement of synoviocytes in OA cartilage degra-
dation through the production of inflammatory and
catabolic mediators [31]. In this regard, pro-inflamma-
tory cytokines such as IL-1b play a role in driving syno-
vitis during OA and influencing the production of
cytokines and MMPs [32]. With respect to the biological
role of HMGB1, it is essential to understand the
mechanisms involved in the regulation of the inflamma-
tory response. HMGB1 appears to act as a pro-inflam-
matory cytokine in mononuclear cells through the
release of TNFa,I L - 1 b,I L - 6 ,I L - 8 ,m a c r o p h a g ei n f l a m -
matory protein-1 and nitric oxide [4,33]. In addition,
HMGB1 stimulates the motility of a wide range of cells
and thus elicits the migration to the site of tissue
damage, a process dependent on the activation of ERK,
NF-B [34] and Src [35] pathways.
Our data first showed that less HMGB1 is observed
in the nuclei of OA synoviocytes, and although a
higher level is found in the cytoplasm and vicinity in
these cells, this did not quite reach statistical signifi-
cance. This lack of significance could be related to the
low number of specimens analysed; however, as
HMGB1 is released extra-cellularly, our evaluation
could be falsely lower. Yet, as there were more cell
layers in OA compared with normal, in addition to the
presence of cell infiltrates in OA showing an elevated
level of HMGB1 in the extra-nuclear compartment
compared with the nuclear, this strongly suggests that
more HMGB1 is released from OA synovial cells than
from normal, supporting the previous data in which
OA cells released HMGB1 upon activation by IL-1b
[16]. We thus hypothesized that HMGB1 may play a
role in modulating the inflammatory process in syno-
vium during OA. Our results indicate that HMGB1
cooperates with IL-1b to amplify the inflammatory
response leading to the production of a number of
cytokines, chemokines and MMPs in OA synoviocytes.
Data showed that HMGB1 plus IL-1b synergistically
Figure 2 Confocal analysis of HMGB1 expression in human synovium. Representative immunohistochemical sections of human (a, c)
normal (n = 3) and (b, d) osteoarthritic (n = 3) synovium with high mobility group box 1 (HMGB1) revealed in fluorescence and read with
confocal microscopy. (e) represents immunohistochemistry revealed in 3,3’-diaminobenzidine (DAB) of human osteoarthritic synovium infiltrates,
and (f) is as (e) but revealed with the fluorescent antibody. The colour green represents HMGB1 and blue the nucleus. Original magnification ×
100. (c) and (d) were amplified by the image processor software.
García-Arnandis et al. Arthritis Research & Therapy 2010, 12:R165
http://arthritis-research.com/content/12/4/R165
Page 6 of 12enhanced IL-6 production, which is in line with a
recent report on the stimulation of IL-6 release by pre-
formed complexes of HMGB1 (100 ng/ml) and IL-1b
at a low concentration unable to stimulate synovio-
cytes (0.05 ng/ml). Interestingly, the response of syno-
vial fibroblasts from OA or rheumatoid arthritis
patients was similar [36].
Chemokines such as IL-8, CCL2 and CCL20 are pro-
duced by OA synoviocytes, but to a lower extent than
rheumatoid arthritis cells. These mediators have the abil-
ity to attract inflammatory cells and regulate gene
transcription and cell proliferation [37]. The up-regula-
tion of chemokines upon IL-1b synoviocyte stimulation
promotes inflammation and cartilage degradation
through the activation of MMPs and other degradative
enzymes [38]. CCL2 and CCL20 are chemokines impli-
cated in rheumatoid arthritis synovitis [39-41] and are
produced by OA synovium in the presence of pro-inflam-
matory cytokines. In particular, IL-1b has been shown to
be a more potent inducer of CCL20 than TNFa or IL-17
[42]. Our data revealed that HMGB1 acted on OA syno-
viocytes in vitro to enhance the production of IL-8, CCL2
and CCL20. The best studied CXC chemokine is IL-8,
which is produced by fibroblasts and macrophages pre-
sent in synovial tissues [43]. Induction of synovial macro-
phage and fibroblast chemotaxis has been demonstrated
for CCL2 [40,44], whereas CCL20 induces monocyte and
Figure 3 Effect of HMGB1 and IL-1b on the levels of cytokine and
chemokine released into the medium by osteoarthritic
synoviocytes. (a) IL-6, (b) IL-8, (c) CCL2 and (d) CCL20 protein levels.
Cells were stimulated with IL-1b (10 ng/ml) for 24 hours in the
presence or absence of high mobility group box 1 (HMGB1) at 15 and
25 ng/ml. Protein levels were determined in supernatants by ELISA.
Data are expressed as mean ± standard error of the mean. Duplicate
samples from six patients were used. ++P < 0.01 with respect to
nonstimulated cells. *P <0 . 0 5 ,* * P < 0.01 with respect to IL-1b.
Figure 4 Effect of HMGB1 and IL-1b on cytokine and
chemokine mRNA levels in OA synoviocytes. (a) IL-6, IL-8, and
(b) CCL2 and CCL20 mRNA relative expression. Cells were
stimulated with IL-1b (10 ng/ml) for 24 hours in the presence or
absence of high mobility group box 1 (HMGB1) at 15 and 25 ng/ml.
mRNA expression was determined by real-time PCR. Data are
expressed as mean ± standard error of the mean. Duplicate samples
from four patients were used. ++P < 0.01 with respect to
nonstimulated cells. *P < 0.05 with respect to IL-1b.
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to the rheumatoid joint [45]. Therefore, the enhanced
production of these mediators in the presence of
HMGB1 supports a role for this protein in the amplifica-
tion of the inflammatory response induced by IL-1b in
OA synoviocytes.
MMPs play an important role in articular tissue degra-
dation in OA. The present study demonstrated the poten-
tiating effect of HMGB1 on IL-1b induction of MMP-1
and MMP-3 in human OA synoviocytes. As MMP-1
degrades collagens in the extracellular matrix [46-48] and
MMP-3 activity leads to activation of collagenases [49],
our results suggest the amplification of catabolic responses
by HMGB1 during joint inflammation.
Several studies indicate that spontaneous or stimulated
production of many inflammatory and degradative med-
iators by OA synoviocytes are related to NF-B activa-
tion [50,51]. In particular, transcription of IL-6 [52],
IL-8 [53], CCL2, CCL20 [41,54] and MMPs [55,56] is
NF-B dependent. Our data show that IL-1b plus
HMGB1 synergistically increased the transcriptional
activity of NF-B, leading to an enhanced production of
inflammatory and catabolic mediators.
MAPK activity regulates the activation of transcription
factors relevant in inflammatory responses [57]. We
Figure 5 Effect of HMGB1 and IL-1b on the levels of MMP
released into the medium by osteoarthritic synoviocytes. (a)
Matrix metalloproteinase (MMP)-1, (b) MMP-3 and (c) MMP-13
protein levels in the medium. Cells were stimulated with IL-1b (10
ng/ml) for 24 hours in the presence or absence of high mobility
group box 1 (HMGB1) at 15 and 25 ng/ml. MMP protein was
measured by ELISA in supernatants. Data are expressed as mean ±
standard error of the mean. Duplicate samples from six to eight
patients were used. ++P < 0.01 with respect to nonstimulated cells.
*P < 0.05, **P < 0.01 with respect to IL-1b.
Figure 6 Effect of HMGB1 and IL-1b on MMP mRNA levels in
osteoarthritic synoviocytes and MMP activity released into the
medium. (a) Matrix metalloproteinase (MMP)-1, MMP-3 and MMP-13
mRNA levels and (b) MMP activity. Cells were stimulated with IL-1b
(10 ng/ml) for 24 hours in the presence or absence of high mobility
group box 1 (HMGB1) at 15 and 25 ng/m. mRNA was determined
by real-time PCR and MMP activity was measured in supernatants
by a fluorometric procedure, as indicated in Materials and Methods.
Data are expressed as mean ± standard error of the mean.
Duplicate samples from four patients were used. ++P < 0.01 with
respect to nonstimulated cells. *P < 0.05, **P < 0.01 with respect to
IL-1b.
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tion, which participates in IL-6 and IL-8 transcription in
human fibroblast-like synoviocytes [58,59]. As the pro-
duction of MMP-1 and MMP-3 upon stimulation of
synoviocytes with IL-1b depends on ERK activation [60],
we investigated the effects of HMGB1 on ERK phos-
phorylation. Our results indicate that HMGB1 potenti-
ates the effects of IL-1b on ERK phosphorylation, which
m a yp l a yar o l ei nt h eu p - r e g u l a t i o no fM M P - 1a n d
MMP-3 by HMGB1. In contrast, we did not observe any
modification of JNK1/2, which phosphorylates c-Jun and
regulates the transcription factor activating protein-1
[61] as well as erythroblastosis 26 transcription factors
[62]. Interestingly, HMGB1 potentiates Akt phosphory-
lation by IL-1b,ap a t h w a yi n v o l v e di nc e l ls u r v i v a la n d
proliferation of fibroblasts in rheumatoid arthritis syno-
vium [63]. In addition, Akt activation may play a role in
human cartilage breakdown, because it has been impli-
cated in MMP-13 and aggrecanase-1 expression induced
by oncostatin M [64] and the synergistic induction of
MMP-1 and MMP-13 expression after oncostatin M
+IL-1b stimulation of human chondrocytes [65]. Our
data would therefore suggest that the potentiation of
ERK, p38 and Akt activation by HMGB1 may be a
mechanism relevant for the increase in the intensity and
persistence of synovitis as well as the expression of cata-
bolic factors in OA.
Conclusions
HMGB1 is overexpressed in synovial membranes of OA
patients. The results presented here support the view that
HMGB1 would act as a pro-inflammatory cytokine, which
enhances the OA synovial inflammatory process. HMGB1
was found to synergize with IL-1b to induce phosphoryla-
tion of ERK1/2, p38 and Akt, as well as NF-B activation.
These effects result in the production of pro-inflammatory
and catabolic mediators that would contribute to synovitis
and articular destruction during OA.
Figure 7 Effect of HMGB1 and IL-1b on Akt and MAPK
phosphorylation. Cells were stimulated with IL-1b (10 ng/ml) for
five minutes in the presence or absence of high mobility group box
1 (HMGB1) at 15 and 25 ng/ml. Protein level was determined in cell
lysates by western blotting by using specific antibodies against
phosphorylated or total proteins. Relative expression of
phosphorylated and total protein bands was calculated after
densitometric analysis. Data are expressed as mean ± standard error
of the mean (samples from three patients). ++P < 0.01 with respect
to nonstimulated cells. *P < 0.05, with respect to IL-1b. ERK,
extracellular signal-regulated kinase; JNK, c-Jun N-terminal kinase;
MAPK, mitogen-activated protein kinase.
Figure 8 Effect of HMGB1 and IL-1b on NF-Ba c t i v a t i o n .
Transient transfection was performed with the reporter construct
nuclear factor (NF)-B-luc and the internal control pRL-TK, as
indicated in Materials and Methods. Cells were treated for 24 hours
with high mobility group box 1 (HMGB1) at 25 ng/ml in the
absence or presence of IL-1b (10 ng/ml). Firefly luciferase activity
was normalized to Renilla luciferase activity. Data are expressed as
mean ± standard error of the mean. Duplicate samples from six
patients were used. ++P < 0.01 with respect to nonstimulated cells;
*P < 0.05 with respect to IL-1b.
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Additional file 1: Supplementary figure S1. Time course of high
mobility group box 1 (HMGB1) and IL-1b effects on Akt and mitogen-
activated protein kinase (MAPK) phosphorylation.
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